Amicus Therapeutics fat disorder drug effective in trial
April 29 (Reuters) - Amicus Therapeutics Inc said its lead drug to treat fat-storage disorder was found effective in patients after 12 months of treatment in a late-stage trial.
The company's shares jumped about 33 percent in premarket trading. They closed at $1.84 on the Nasdaq on Monday.
The trial evaluated the drug, migalastat, as a form of monotherapy for Fabry disease patients. (Reporting by Natalie Grover in Bangalore; Editing by Don Sebastian)
- Scots vote on independence, United Kingdom's fate on knife-edge |
- Islamic State shows captive British journalist in new video
- Australian PM says police raids follow IS linked beheading plot |
- New evacuations ordered as California wildfire doubles in size |
- Chinese hacked U.S. military contractors: Senate panel